You are here
Biomaterials for mRNA based cellular reprogramming
Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R43TR001904-01
Agency Tracking Number: R43TR001904
Amount:
$290,999.00
Phase:
Phase I
Program:
SBIR
Solicitation Topic Code:
100
Solicitation Number:
PA14-307
Timeline
Solicitation Year:
2014
Award Year:
2017
Award Start Date (Proposal Award Date):
2017-02-01
Award End Date (Contract End Date):
2018-07-31
Small Business Information
808 WILLIAMSON ST STE 402, Madison, WI, 53703-4085
DUNS:
079733405
HUBZone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Principal Investigator
Name: CONNIE LEBAKKEN
Phone: (608) 239-2669
Email: connielebakken@gmail.com
Phone: (608) 239-2669
Email: connielebakken@gmail.com
Business Contact
Name: CONNIE LEBAKAKEN
Phone: (608) 239-2669
Email: connie.lebakken@stempharminc.com
Phone: (608) 239-2669
Email: connie.lebakken@stempharminc.com
Research Institution
N/A
Abstract
Project Summary Abstract
Induced pluripotent stem cells iPSCs hold great promise in the areas of disease modeling and
regenerative medicine and as a result have unique commercial potential There are currently more than
ongoing clinical trials in stem cell therapies including the first in human trial using human iPSC
derived retinal pigment epithelial cells to treat macular degeneration Another set of recent studies have
shown direct reprogramming of target cells e g fibroblasts into neural or cardiac cell types via delivery
of genes encoding tissue specific transcription factors These scientific advances may lead to new
avenues for treatment of human diseases These potential therapeutic applications in addition to the
potential of reprogrammed human cells as unique research tools frame a substantial commercial
opportunity The initial and currently most commonly used methods of cellular reprogramming use
retroviral vectors to deliver reprogramming factors into the cells This method results in random
integration of reprogramming factors into the genome which is highly problematic for clinical use Non
integrative methods of delivering reprogramming factors include the use of episomal DNA or Sendai
Virus These methods work well for a variety of cell types however they require monitoring for vector
or viral clearance resulting in a longer workflow and increased labor and reagent costs There is a need
to develop commercial tools for safe efficient and adaptable cellular reprogramming with a particular
emphasis on non viral approaches for research and therapy A promising avenue for reprogramming
cells involves delivering mRNA that encodes reprogramming factors Using mRNA is especially attractive
as it dramatically reduces the risk of genomic integration and reduces the time required for clearance of
the reprogramming factors The goal of this proposed Phase I Project is to develop an mRNA delivery
system utilizing mineral coated microparticles and apply this innovative system for the generation of
foot print free iPSCs from clinically relevant cell types Specific aim will utilize our mineral coated
microparticles to deliver mRNA encoding fluorescent reporter proteins for the optimization of
transfection conditions to fibroblasts and blood derived cells Specific aim will use the optimized
conditions to deliver mRNA encoding reprogramming factors to fibroblasts and blood derived cells to
generate iPSCs which will be characterized for pluripotency expansion capability and karyotype stability
This work is significant as it will improve the work flow for mRNA reprogramming in fibroblasts and will
enable derivation of iPSCs from patient blood cells utilizing mRNA reprogramming This work is
innovative as it will improve mRNA delivery methods for these and other cell types which will lead to
further utilization of this technology in direct reprogramming differentiation and in vivo applications Public Health Relevance
Induced pluripotent stem cells have enormous promise for regenerative medicine and treating diseases
but researchers need better methods to generate those stem cells from patient samples We will
develop a new transfection technology to deliver mRNA to cells from patient samples to reprogram
those cells to the pluripotent state * Information listed above is at the time of submission. *